The inversion or translocation of chromosome 3 drives inv(3)/t(3;3) AML via structural rearrangement of an enhancer that upregulates transcription of EVI1. It is associated with poor overall survival in AML patients and HSCT is usually mandated whenever possible (43). The gene discussed is RUNX1; the disease is acute myeloid leukemia.